These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 29348610)
1. The histone methyltransferase DOT1L inhibits osteoclastogenesis and protects against osteoporosis. Gao Y; Ge W Cell Death Dis; 2018 Jan; 9(2):33. PubMed ID: 29348610 [TBL] [Abstract][Full Text] [Related]
2. Cutting Edge: EZH2 Promotes Osteoclastogenesis by Epigenetic Silencing of the Negative Regulator IRF8. Fang C; Qiao Y; Mun SH; Lee MJ; Murata K; Bae S; Zhao B; Park-Min KH; Ivashkiv LB J Immunol; 2016 Jun; 196(11):4452-4456. PubMed ID: 27183582 [TBL] [Abstract][Full Text] [Related]
3. Crucial Role of Lysine-Specific Histone Demethylase 1 in RANKL-Mediated Osteoclast Differentiation. Ding M; Chen Z; Cho E; Park SW; Lee TH Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835016 [TBL] [Abstract][Full Text] [Related]
4. METTL14 represses osteoclast formation to ameliorate osteoporosis via enhancing GPX4 mRNA stability. Deng M; Luo J; Cao H; Li Y; Chen L; Liu G Environ Toxicol; 2023 Sep; 38(9):2057-2068. PubMed ID: 37195267 [TBL] [Abstract][Full Text] [Related]
5. The chromatin remodeling factor Arid1a cooperates with Jun/Fos to promote osteoclastogenesis by epigenetically upregulating Siglec15 expression. Zhang Y; Sun H; Huang F; Chen Y; Ding X; Zhou C; Wu Y; Zhang Q; Ma X; Wang J; Yue R; Shen L; Sun X; Ye Z J Bone Miner Res; 2024 Jul; 39(6):775-790. PubMed ID: 38477755 [TBL] [Abstract][Full Text] [Related]
6. DDR2 (discoidin domain receptor 2) suppresses osteoclastogenesis and is a potential therapeutic target in osteoporosis. Zhang Y; Su J; Wu S; Teng Y; Yin Z; Guo Y; Li J; Li K; Yao L; Li X Sci Signal; 2015 Mar; 8(369):ra31. PubMed ID: 25805889 [TBL] [Abstract][Full Text] [Related]
7. Xanthotoxin prevents bone loss in ovariectomized mice through the inhibition of RANKL-induced osteoclastogenesis. Dou C; Chen Y; Ding N; Li N; Jiang H; Zhao C; Kang F; Cao Z; Quan H; Luo F; Xu J; Dong S Osteoporos Int; 2016 Jul; 27(7):2335-2344. PubMed ID: 26809192 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of PRMT5 suppresses osteoclast differentiation and partially protects against ovariectomy-induced bone loss through downregulation of CXCL10 and RSAD2. Dong Y; Song C; Wang Y; Lei Z; Xu F; Guan H; Chen A; Li F Cell Signal; 2017 Jun; 34():55-65. PubMed ID: 28302565 [TBL] [Abstract][Full Text] [Related]
9. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically. Valverde P; Tu Q; Chen J J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638 [TBL] [Abstract][Full Text] [Related]
10. Euphorbia factor L1 inhibits osteoclastogenesis by regulating cellular redox status and induces Fas-mediated apoptosis in osteoclast. Hong SE; Lee J; Seo DH; In Lee H; Ri Park D; Lee GR; Jo YJ; Kim N; Kwon M; Shon H; Kyoung Seo E; Kim HS; Young Lee S; Jeong W Free Radic Biol Med; 2017 Nov; 112():191-199. PubMed ID: 28774817 [TBL] [Abstract][Full Text] [Related]
11. Tea polysaccharide inhibits RANKL-induced osteoclastogenesis in RAW264.7 cells and ameliorates ovariectomy-induced osteoporosis in rats. Xu H; Yin D; Liu T; Chen F; Chen Y; Wang X; Sheng J Biomed Pharmacother; 2018 Jun; 102():539-548. PubMed ID: 29587240 [TBL] [Abstract][Full Text] [Related]
12. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637 [TBL] [Abstract][Full Text] [Related]
13. Siglec-15 is a potential therapeutic target for postmenopausal osteoporosis. Kameda Y; Takahata M; Mikuni S; Shimizu T; Hamano H; Angata T; Hatakeyama S; Kinjo M; Iwasaki N Bone; 2015 Feb; 71():217-26. PubMed ID: 25460183 [TBL] [Abstract][Full Text] [Related]
14. A potential therapeutic target for regulating osteoporosis via suppression of osteoclast differentiation. Sun Q; Zhang B; Zhu W; Wei W; Ma J; Tay FR J Dent; 2019 Mar; 82():91-97. PubMed ID: 30716449 [TBL] [Abstract][Full Text] [Related]
15. Nanoemulsified Genistein and Vitamin D Mediated Epigenetic Regulation to Inhibit Osteoporosis. Kushwaha AC; Mohanbhai SJ; Sardoiwala MN; Jaganathan M; Karmakar S; Roy Choudhury S ACS Biomater Sci Eng; 2022 Sep; 8(9):3810-3818. PubMed ID: 36005299 [TBL] [Abstract][Full Text] [Related]
16. The DOT1L-MLLT10 complex regulates male fertility and promotes histone removal during spermiogenesis. Lin H; Cossu IG; Leu NA; Deshpande AJ; Bernt KM; Luo M; Wang PJ Development; 2023 May; 150(9):. PubMed ID: 37082953 [TBL] [Abstract][Full Text] [Related]
17. DOT1L decelerates the development of osteoporosis by inhibiting SRSF1 transcriptional activity via microRNA-181-mediated KAT2B inhibition. Wang C; Chen R; Zhu X; Zhang X; Lian N Genomics; 2024 Jan; 116(1):110759. PubMed ID: 38072145 [TBL] [Abstract][Full Text] [Related]
18. Targeted disruption of the histone lysine 79 methyltransferase Dot1L in nephron progenitors causes congenital renal dysplasia. Wang F; Ngo J; Li Y; Liu H; Chen CH; Saifudeen Z; Sequeira-Lopez MLS; El-Dahr SS Epigenetics; 2021 Nov; 16(11):1235-1250. PubMed ID: 33315499 [TBL] [Abstract][Full Text] [Related]
19. Effects of bisphosphonates on osteoclastogenesis in RAW264.7 cells. Abe K; Yoshimura Y; Deyama Y; Kikuiri T; Hasegawa T; Tei K; Shinoda H; Suzuki K; Kitagawa Y Int J Mol Med; 2012 Jun; 29(6):1007-15. PubMed ID: 22447156 [TBL] [Abstract][Full Text] [Related]
20. Emodin regulates bone remodeling by inhibiting osteoclastogenesis and stimulating osteoblast formation. Kim JY; Cheon YH; Kwak SC; Baek JM; Yoon KH; Lee MS; Oh J J Bone Miner Res; 2014 Jul; 29(7):1541-53. PubMed ID: 25832436 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]